Basit öğe kaydını göster

dc.contributor.authorRossini, Paolo Maria
dc.contributor.authorDi Iorio, Riccardo
dc.contributor.authorVecchio, F.
dc.contributor.authorAnfossi, Maria
dc.contributor.authorBabiloni, C.
dc.contributor.authorBozzali, M.
dc.contributor.authorBruni, Amalia Cecilia
dc.contributor.authorCappa, Stefano F.
dc.contributor.authorEscudero, Julien
dc.contributor.authorFraga, Francisco Jose
dc.contributor.authorGiannakopoulos, Panteleimon
dc.contributor.authorGüntekin, Bahar
dc.contributor.authorLogroscino, Giancarlo
dc.contributor.authorMarra, Camillo
dc.contributor.authorMiraglia, F.
dc.contributor.authorPanza, Francesco
dc.contributor.authorTecchio, F.
dc.contributor.authorPascual-Leone, Alvaro
dc.contributor.authorDubois, Bruno
dc.date.accessioned2020-07-28T08:04:11Z
dc.date.available2020-07-28T08:04:11Z
dc.date.issued2020en_US
dc.identifier.citationRossini, P. M., Di Iorio, R., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M. ... Dubois, B. (2020). Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. Clinical Neurophysiology, 131(6), 1287-1310. https://dx.doi.org/10.1016/j.clinph.2020.03.003en_US
dc.identifier.issn1388-2457
dc.identifier.issn1872-8952
dc.identifier.urihttps://dx.doi.org/10.1016/j.clinph.2020.03.003
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5622
dc.description.abstractAlzheimer's disease (AD) is the most common neurodegenerative disease among the elderly with a progressive decline in cognitive function significantly affecting quality of life. Both the prevalence and emotional and financial burdens of AD on patients, their families, and society are predicted to grow significantly in the near future, due to a prolongation of the lifespan. Several lines of evidence suggest that modifications of risk-enhancing life styles and initiation of pharmacological and nonpharmacological treatments in the early stage of disease, although not able to modify its course, helps to maintain personal autonomy in daily activities and significantly reduces the total costs of disease management. Moreover, many clinical trials with potentially disease-modifying drugs are devoted to prodromal stages of AD. Thus, the identification of markers of conversion from prodromal form to clinically AD may be crucial for developing strategies of early interventions. The current available markers, including volumetric magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebral spinal fluid (CSF) analysis are expensive, poorly available in community health facilities, and relatively invasive. Taking into account its low cost, widespread availability and non-invasiveness, electroencephalography (EEG) would represent a candidate for tracking the prodromal phases of cognitive decline in routine clinical settings eventually in combination with other markers. In this scenario, the present paper provides an overview of epidemiology, genetic risk factors, neuropsychological, fluid and neuroimaging biomarkers in AD and describes the potential role of EEG in AD investigation, trying in particular to point out whether advanced analysis of EEG rhythms exploring brain function has sufficient specificity/sensitiv ity/accuracy for the early diagnosis of AD.en_US
dc.description.sponsorshipH2020 Marie S. Curie ITN-ETN project Turkish Academy of Sciences (TUBA), Turkey, The Young Scientists Award Programme (GEBIP) Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)en_US
dc.language.isoengen_US
dc.publisherElsevier Ireland Ltd.en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAlzheimer's Diseaseen_US
dc.subjectMild Cognitive Impairmenten_US
dc.subjectDementiaen_US
dc.subjectAD Biomarkersen_US
dc.subjectEEG Analysisen_US
dc.subjectEEG Rhythmsen_US
dc.subjectEvent-Related Responsesen_US
dc.subjectEarly Diagnosisen_US
dc.titleEarly diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of expertsen_US
dc.typereviewen_US
dc.relation.ispartofClinical Neurophysiologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyofizik Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)en_US
dc.authorid0000-0002-0860-0524en_US
dc.identifier.volume131en_US
dc.identifier.issue6en_US
dc.identifier.startpage1287en_US
dc.identifier.endpage1310en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.1016/j.clinph.2020.03.003en_US
dc.identifier.wosqualityQ2en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster